{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:48:43Z","timestamp":1791082123641,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ejca.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T09:57:17Z","timestamp":1321005437000},"page":"2706-2714","source":"Crossref","is-referenced-by-count":32,"title":["Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00486538","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nizar M.","family":"Tannir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ning","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Scappaticci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Ricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dror Michaelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.09.002_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/14737159.9.1.75","article-title":"Management of metastatic renal cell carcinoma: current trends","volume":"9","author":"Mohammed","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ejca.2011.09.002_b0010","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1200\/JCO.2009.21.8461","article-title":"Targeting renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1758834009338430","article-title":"Review: systemic therapy for advanced renal cell carcinoma","volume":"1","author":"Larkin","year":"2009","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0020","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2011.09.002_b0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.ejca.2011.09.002_b0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2005.07.093","article-title":"A multitargeted, metronomic, and maximum-tolerated dose \u2018chemo-switch\u2019 regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer","volume":"23","author":"Pietras","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0035","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/01.ju.0000165693.68449.c3","article-title":"Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy","volume":"173","author":"Lam","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2011.09.002_b0040","unstructured":"Bayer Healthcare Pharmaceuticals, Inc., Sorafenib [package insert]. Emeryville, CA. 2009. http:\/\/berlex.bayerhealthcare.com\/html\/products\/pi\/Nexavar_PI.pdf."},{"key":"10.1016\/j.ejca.2011.09.002_b0045","unstructured":"Pfizer Labs. Sunitinib [package insert]. New York, NY. 2008. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=607."},{"key":"10.1016\/j.ejca.2011.09.002_b0050","unstructured":"GlaxoSmithKline. Pazopanib [package insert]. Research Triangle Park, NC. 2009. http:\/\/us.gsk.com\/products\/assets\/us_votrient.pdf."},{"key":"10.1016\/j.ejca.2011.09.002_b0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.09.002_b0060","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.09.002_b0065","unstructured":"Wyeth Pharmaceuticals, Inc., Temsirolimus [package insert]. Philadelphia, PA. 2008. http:\/\/www.wyeth.com\/content\/showlabeling.asp?id=490."},{"key":"10.1016\/j.ejca.2011.09.002_b0070","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0075","article-title":"A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab","volume":"26","author":"Shepard","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2011.09.002_b0080","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","article-title":"Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer","volume":"27","author":"Di Lorenzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0085","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0090","unstructured":"Novartis Pharma Stein AG. Everolimus [package insert]. Stein, Switzerland. 2009. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf."},{"key":"10.1016\/j.ejca.2011.09.002_b0095","unstructured":"National Institutes of Health: A randomized trial of temsirolimus versus sorafenib as second-line therapy in patients with advanced renal cell carcinoma who have failed first-line sunitinib therapy. Protocol: (NCT00474786). http:\/\/www.clinicaltrials.gov\/."},{"key":"10.1016\/j.ejca.2011.09.002_b0100","unstructured":"National Institutes of Health: Axitinib (AG 013736) As second line therapy for metastatic renal cell cancer: Axis trial. Protocols: (NCT00678392). http:\/\/www.clinicaltrials.gov\/."},{"key":"10.1016\/j.ejca.2011.09.002_b0105","article-title":"Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial","volume":"29","author":"Rini","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2011.09.002_b0110","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1535-7163.MCT-05-0410","article-title":"Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor","volume":"5","author":"Albert","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.09.002_b0115","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1200\/JCO.2008.21.7125","article-title":"Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies","volume":"27","author":"Wong","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0120","unstructured":"National Institutes of Health: An open-label, phase 2 study to evaluate the efficacy and tolerability of ABT-869 in subjects with advanced renal cell carcinoma (RCC) who have previously received treatment with sunitinib. Protocol: (NCT00486538). http:\/\/www.clinicaltrials.gov\/."},{"key":"10.1016\/j.ejca.2011.09.002_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.09.002_b0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bjc.6603515","article-title":"DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents","volume":"96","author":"O\u2019Connor","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.09.002_b0135","first-page":"1431","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2011.09.002_b0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.09.002_b0145","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan\u2013Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2011.09.002_b0150","unstructured":"NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"10.1016\/j.ejca.2011.09.002_b0155","series-title":"Applied Biopharmaceutics and Pharmacokinetics","author":"Shargel","year":"2005"},{"key":"10.1016\/j.ejca.2011.09.002_b0160","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis","volume":"4","author":"W\u00e4hlby","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ejca.2011.09.002_b0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.09.002_b0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.09.002_b0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.09.002_b0180","unstructured":"National Institutes of Health: Efficacy and tolerability of ABT-869 versus sorafenib in advanced hepatocellular carcinoma (HCC). Protocol: (NCT01009593). http:\/\/www.clinicaltrials.gov\/."},{"key":"10.1016\/j.ejca.2011.09.002_b0185","article-title":"Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy","volume":"29","author":"Posadas","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911007131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T07:59:55Z","timestamp":1560931195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911007131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0959804911007131"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.09.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}